2 days ago

Merck & Co. (MRK) Stock: Rises as EU Backs Expanded RSV Drug Approval

TLDR Merck stock climbs 0.65% to $147.90 after positive EU opinion on ENFLONSIA. EU advisers back ENFLONSIA use for high-risk children through a second RSV season. European Commission decision on Merck’s expanded RSV treatment is due in two months. Phase 3 SMART trial data support Merck’s bid to expand RSV prevention in Europe. FDA sets [...]

The post Merck & Co. (MRK) Stock: Rises as EU Backs Expanded RSV Drug Approval appeared first on Blockonomi.

Source: Blockonomi →